https://www.selleckchem.com/pr....oducts/Rapamycin.htm
A red blood cell membrane (RBCm)-derived drug delivery system allows prolonged circulation of an antitumor treatment and overcomes the issue of accelerated blood clearance induced by PEGylation. However, RBCm-derived drug delivery systems are limited by low drug-loading capacities and the lack of tumor-targeting ability. Thus, new designs of RBCm-based delivery systems are needed. Herein, we designed hyaluronic acid (HA)-hybridized RBCm (HARBCm)-coated lipid multichambered nanoparticles (HARBCm-LCNPs) to remedy the limitatio
Like
Comment
Share
